NYXOAH SA IPO Advisory
Share this IPO Profile:Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on NYXOAH SA, and our comprehensive analysis, click "Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| NYXOAH SA | NYXH - NASDAQ |
$30.88-$30.88 | $30.00 | $30.02 | 2.835 million | 7/1/2021 |
| Piper Sandler, Stifel, Cantor | ||||||
Co-Manager(s): Degroof Petercam
| ||||||
| Health Care | ||||||
Filing(s): Filed 2021-06-10 Terms Added 2021-06-25 | ||||||
NYXOAH SA Quote & Chart - Click for current quote - NYXH
IPO Boutique aggregates information on public companies and private companies, such as "NYXH" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About NYXOAH SA (adapted from NYXOAH SA prospectus):
They are a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, or OSA.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, or OSA.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "NYXH" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.